Skip to main content

Table 1 Clinical and demographic characteristics of patients

From: Synovial tissue features associated with poor prognosis in inflammatory arthritis

 

Total

RA

PsA

UA

P

N

88

26

33

29

 

Female, n (%)

52 (59.77)

20 (76.92)

14 (42.42)

18 (62.06)

0.026

Smoking, n (%)

13 (14.94)

5 (19.23)

3 (9.09)

5 (17.24)

0.657

Age, mean years (SD)

50.55 (14.93)

53.2 (14.2)

51.4 (13.7)

47.24 (16.5)

0.318

Disease duration, mean months (SD)

60.18 (84.12)

83.3 (113.2)

60.7 (70.9)

29.5 (50.8)

0.581

GC, n (%)

23 (26.43)

13 (50)

5 (15.15)

5 (17.24)

0.010

MTX, n (%)

31 (35.22)

11 (42.30)

12 (36.36)

8 (27.58)

0.257

LEF, n (%)

2 (2.27)

1 (3.86)

1 (3.06)

-

0.192

SSZ, n (%)

4 (4.49)

-

-

4 (13.79)

0.014

Development of bone erosion, n (%)

19 (21.59)

7 (26.92)

4 (12.12)

8 (27.58)

0.181

ACPA positive, n (%)

27 (31.03)

19 (73.07)

-

8 (27.58)

0.007

RF positive, n (%)

24 (27.58)

16 (61.53)

-

8 (27.58)

0.001

HLB 27 positive, n (%)

15 (17.24)

-

9 (27.27)

6 (20.68)

0.018

DAS28 CRP mean (SD)

3.00 (0.92)

3.44 (1.1)

2.65 (0.6)

3.00 (0.9)

0.004

DAS28 ERS, mean (SD)

3.89 (1.19)

4.31 (1.5)

3.46 (1)

4.34 (1.2)

0.013

Initiation of bDMARDS, n (%)

35 (39.77)

13 (50)

10 (30.30)

12 (41.37)

0.301

BMI, mean (SD)

34.30 (26.27)

25 (3.84)

27.96 (3.70)

25,09 (3.33)

0.340

Dyslipidemia, n (%)

17 (19.31)

3 (11.53)

11 (33.33)

3 (10.34)

0.023

Type 2 DM

15 (17.04)

2 (7.69)

10 (30.30)

3 (10.34)

0.019

HBP

38 (43.18)

12 (46.15)

16 (48.48)

10 (34.48)

0.274

  1. GC glucocorticoids, MTX methotrexate, LEF leflunomide, SSZ sulfasalazine; ACPA anti-citrullinated protein antibodies, RF rheumatoid factor, DAS28 CRP Disease Activity Score-28 C-reactive protein, DAS28 ERS Disease Activity Score-28 erythrocyte sedimentation rate, BMI body mass index, T2DM type 2 diabetes mellitus, HBP high blood pressure